Detalhe da pesquisa
1.
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
N Engl J Med
; 379(1): 22-31, 2018 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29972757
2.
Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers.
Mol Ther
; 24(10): 1771-1782, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27357629
3.
Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events.
Clin Transl Sci
; 16(4): 575-580, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36631935
4.
Integrated Assessment of Phase 2 Data on GalNAc3-Conjugated 2'-O-Methoxyethyl-Modified Antisense Oligonucleotides.
Nucleic Acid Ther
; 33(1): 72-80, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36454263
5.
Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear Cells.
Nucleic Acid Ther
; 32(6): 457-472, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35976085
6.
Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus-Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses.
Clin Pharmacol Drug Dev
; 11(10): 1191-1202, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35971951
7.
Improvements in the Tolerability Profile of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in Parallel with Advances in Design, Screening, and Other Methods.
Nucleic Acid Ther
; 31(6): 417-426, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34242101
8.
Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.
Nat Med
; 27(10): 1725-1734, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34642494
9.
Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.
J Lipid Res
; 51(5): 1057-62, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20008831
10.
Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia.
Nucleic Acid Ther
; 30(2): 94-103, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043907
11.
The Effects of 2'-O-Methoxyethyl Oligonucleotides on Renal Function in Humans.
Nucleic Acid Ther
; 28(1): 10-22, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29185862
12.
The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials.
Nucleic Acid Ther
; 27(3): 121-129, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28145801
13.
Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment.
Antivir Ther
; 9(6): 953-68, 2004 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-15651754
14.
Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.
J Thorac Oncol
; 4(9): 1156-62, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19704336
15.
A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients.
J Hepatol
; 44(1): 88-96, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16274834
16.
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.
Invest New Drugs
; 23(5): 467-77, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16133798